|
A new medicines trade and health security agenda for the European Commission |
Medicines for Europe |
Fri, 02/19/2021 |
Health & Consumers |
|
2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments |
Medicines for Europe |
Tue, 09/12/2017 |
Health & Consumers |
|
2018 – A year of unprecedented challenges and opportunities for pharmaceutical regulatory systems |
Medicines for Europe |
Thu, 01/25/2018 |
Health & Consumers |
|
2022 Health at a Glance Report highlights the need to rethink investments in health after the COVID-19 pandemic |
Medicines for Europe |
Mon, 12/05/2022 |
Health & Consumers |
|
62% of Medicines Dispensed in Europe are Generic, according to IMS New Data |
Medicines for Europe |
Thu, 06/15/2017 |
Health & Consumers |
|
A DIGITAL FUTURE FOR VALUE ADDED MEDICINES – IQVIA publication shares the future of the sector |
Medicines for Europe |
Tue, 09/24/2019 |
Health & Consumers |
|
A step forward for the secure supply of medicines and manufacturing and for public health |
Medicines for Europe |
Wed, 10/25/2023 |
Health & Consumers |
|
A streamlined, digital regulatory framework is the foundation for equitable access to medicines |
Medicines for Europe |
Wed, 09/27/2023 |
Health & Consumers |
|
Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries |
Medicines for Europe |
Fri, 11/26/2021 |
Health & Consumers |
|
Access to medicines and security of supply should be central to EU pharma and IP legislation reforms in Europe |
Medicines for Europe |
Tue, 06/13/2023 |
Health & Consumers |
|
Access to medicines critical in European Parliament vote on EU IP action plan |
Medicines for Europe |
Fri, 11/12/2021 |
Health & Consumers |
|
Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest |
Medicines for Europe |
Thu, 06/14/2018 |
Health & Consumers |
|
Addressing medicine shortages in Europe: Competition is crucial for patient access |
Medicines for Europe |
Fri, 09/29/2017 |
Health & Consumers, Competition |
|
Adjustments to IP framework needed to improve access to medicines in Europe |
Medicines for Europe |
Tue, 11/16/2021 |
Science & Policymaking |
|
AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” |
Medicines for Europe |
Wed, 02/03/2021 |
Health & Consumers |
|
Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe |
Medicines for Europe |
Fri, 10/01/2021 |
Health & Consumers |
|
Billions more euros to re-invest in better healthcare thanks to biosimilar medicines |
Medicines for Europe |
Wed, 12/14/2022 |
Health & Consumers |
|
Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health systems |
Medicines for Europe |
Thu, 12/16/2021 |
Health & Consumers |
|
Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe |
Medicines for Europe |
Tue, 05/09/2017 |
Health & Consumers |
|
Biosimilar medicines: competition, sustainability and early* access on the agenda of DG GROW stakeholder workshop |
Medicines for Europe |
Wed, 10/30/2019 |
Health & Consumers |
|
Biosimilar Medicines: essential for sustainable access to medicines |
Medicines for Europe |
Fri, 04/27/2018 |
Health & Consumers |
|
Brexit - Life Science Industry Joint Position Paper |
Medicines for Europe |
Thu, 12/14/2017 |
Health & Consumers, UK in Europe |
|
Central & Eastern European patients have inequitable access to medicines for life-threatening conditions |
Medicines for Europe |
Mon, 04/25/2022 |
Health & Consumers |
|
CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court |
Medicines for Europe |
Thu, 09/20/2018 |
Health & Consumers |
|
Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs |
Medicines for Europe |
Wed, 10/18/2017 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
Fri, 12/10/2021 |
Health & Consumers |
|
Competition policy essential for access to medicines |
Medicines for Europe |
Tue, 01/29/2019 |
Health & Consumers |
|
Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe |
Medicines for Europe |
Mon, 05/28/2018 |
Health & Consumers, Social Europe & Jobs |
|
Court decision on Supplementary Protection Certificate (SPC) manufacturing waiver risks undermining its use |
Medicines for Europe |
Thu, 01/18/2024 |
InfoSociety |
|
COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy |
Medicines for Europe |
Thu, 07/09/2020 |
Health & Consumers |
